)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Oncternal Therapeutics (ONCT) investor relations material
Oncternal Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary6 Nov, 2024
Executive summary
Discontinued all clinical trials and product development activities as of September 12, 2024, to explore strategic alternatives including asset sales, licensing, or business combinations.
Initiated a reduction-in-force in September 2024 and will continue to assess further cost reduction measures.
Focused on maximizing stockholder value through potential transactions; no assurance of successful outcomes.
Financial highlights
Net loss of $8.5 million for Q3 2024, compared to $9.9 million in Q3 2023; net loss of $25.4 million for the nine months ended September 30, 2024, versus $30.3 million in the prior year period.
Grant revenue was $0.5 million for Q3 2024 and $1.9 million for the nine months ended September 30, 2024, up from $0.2 million and $0.5 million, respectively, in 2023.
Research and development expenses decreased to $6.4 million in Q3 2024 from $7.5 million in Q3 2023; nine-month R&D expenses were $19.1 million, down from $23.1 million.
General and administrative expenses were $2.7 million in Q3 2024, down from $3.1 million in Q3 2023; nine-month G&A expenses were $9.1 million, down from $9.5 million.
Cash, cash equivalents, and short-term investments totaled $14.6 million as of September 30, 2024, with no debt.
Outlook and guidance
Research and development expenses are expected to decrease significantly as clinical activities are discontinued, with ongoing costs related to trial closures and nonclinical projects.
Management concluded that current cash resources are sufficient to fund operations into Q1 2025, but not for the full twelve months following the report date without additional funding or asset sales.
There is substantial doubt about the company's ability to continue as a going concern for twelve months following the report date.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Oncternal Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies aimed at addressing cancers with critical unmet medical needs. Their diverse pipeline of treatments targets hematological malignancies and prostate cancer through multiple modalities. Their investigational product candidates include ONCT-808, an autologous CAR T cell therapy targeting ROR1 for patients with multiple hematologic and solid malignancies; ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI) for advanced prostate cancer; and Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein expressed in various malignancies. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage